Contract Manufacturing in Pharmaceuticals: How the Industry’s Business Model Is Changing and What Opportunities Are Emerging for Uzbekistan

Business

The development of the pharmaceutical industry depends not only on the creation of new medicines but also on the efficient organization of their production. This stage determines how quickly a drug reaches the market, the level of investment required, the consistency of quality, and the ability to ensure reliable supplies.

Contract Manufacturing in Pharmaceuticals: How the Industry’s Business Model Is Changing and What Opportunities Are Emerging for Uzbekistan
Sergey Beloborodov, CEO of Bayan Group, sees contract development and manufacturing (CDMO — Contract Development and Manufacturing Organization) as a promising business segment. For Uzbekistan, this model could become a tool for strengthening the country’s pharmaceutical manufacturing base and expanding its export potential.

What Is CDMO and Why Is the Model in Demand?

A CDMO company provides pharmaceutical businesses with services covering drug development, technology adaptation, registration, and manufacturing. This allows clients to focus on their own brands, marketing, and sales without investing in the construction and operation of a manufacturing facility.

This model is changing the traditional structure of the industry. Whereas many companies previously sought to control the entire value chain — from development and manufacturing to marketing and distribution — market participants are increasingly specializing in specific areas and partnering with other companies to handle the remaining activities.

Speaking at the international CAPEX exhibition, Sergey Beloborodov noted that the global CDMO market is growing by approximately 7% annually, outpacing the pharmaceutical market as a whole. According to his estimate, a significant share of dosage forms, including tablets and ampoules, is already manufactured with the involvement of contract manufacturers.

Major international players in this segment include Lonza, Samsung Biologics, Catalent, and Thermo Fisher Scientific (Patheon). Their example demonstrates that contract manufacturing has become a strategic business in its own right, rather than simply a way to utilize spare production capacity.

The Economics of Time and Investment

Establishing an in-house pharmaceutical manufacturing facility requires substantial investment. In addition to constructing the site and purchasing equipment, a company must obtain the necessary licenses and registrations, establish a quality management system, train personnel, and ensure compliance with Good Manufacturing Practice (GMP) requirements. All these processes take time and involve ongoing costs.

The contract manufacturing model can reduce initial investment and accelerate the transition to commercial production. A client gains access to an existing facility, equipment, a qualified team, and established processes. Launch timelines depend on the specific product, the readiness of its documentation, registration procedures, and technological requirements. However, in many cases, this approach can be faster than building a manufacturing facility from scratch.

Another advantage is access to the expertise of a specialized manufacturer. Such companies have experience in production processes, quality control, documentation, and regulatory requirements. Clients do not need to develop all these capabilities in-house and can instead direct their resources towards expanding their product portfolios and strengthening their market presence.

One Molecule, Different Brands and Strategies

Contract manufacturing makes it possible to produce a medicine containing the same active ingredient under different trade names for several clients. Each company independently determines the product’s positioning, sales channels, and target audience.

For example, one market participant may specialize in promoting medicines to doctors, another in working with pharmacy chains, and a third in participating in public procurement. Their own brands and commercial strategies allow each company to develop a product in the market segment where it has a competitive advantage. The manufacturer, meanwhile, ensures that the medicine is produced in accordance with the agreed requirements.

As an example, Sergey Beloborodov cited the market for lysine-based medicines, where several trade brands of the same product are available. In his assessment, the emergence of multiple brands can expand a medicine’s market presence, intensify competition, and improve product availability for patients. Contract manufacturing therefore serves not only as a cost-optimization tool but also as a mechanism for market development.

How to Choose a Manufacturing Partner

When selecting a contractor, it is important to consider not only the cost of services and the availability of production capacity but also the role contract orders play in the manufacturer’s business model.

If a company primarily focuses on its own brands, orders from third-party clients may receive less attention. During periods of high production demand, the manufacturer may prioritize its own products, making the timelines for contract orders less predictable.

Speaking about the criteria for selecting a manufacturer, Sergey Beloborodov issued a warning: “You will always be the second or third priority after its own medicines.”

A strategic CDMO partner should therefore have a dedicated team for working with clients, individual account managers, transparent production planning, and clearly defined delivery schedules. Under this model, the contract client becomes a full-fledged partner in a long-term business relationship.

Equally important are the quality management system, the facility’s technical capabilities, experience in manufacturing specific dosage forms, and supply reliability. A manufacturer should be interested not only in fulfilling an order but also in supporting the development of the client’s brand.

“For us, the success of our client’s brand is our success; your growth is our growth,” emphasized the head of Bayan Group.

Regulatory Changes and Opportunities for Uzbekistan

The development of contract manufacturing depends not only on the capabilities of individual companies but also on the regulatory environment. Pharmaceutical businesses need clear state registration procedures, predictable document review timelines, and the opportunity to bring medicines manufactured at local facilities to market.

In Uzbekistan, updated rules for the state registration of medicines came into force on February 26, 2026. They were approved by Cabinet of Ministers Resolution No. 738 dated November 24, 2025. The rules provide for a general registration procedure and a recognition-based procedure for medicines already approved by regulators included in the World Health Organization’s WHO Listed Authorities list or by regulators with a high level of maturity. Priority registration is also предусмотрed for certain categories of medicines.

The application of simplified procedures and the registration of medicines under different trade names depend on the specific conditions and requirements established by law. This does not mean that any number of brands can automatically be registered on the basis of a single registration document.

Improving regulatory mechanisms is important for local manufacturers and their partners. Clear rules make it possible to plan the launch of new products, assess project economics, and establish long-term cooperation.

Uzbekistan has several prerequisites for developing its CDMO sector: a growing domestic market, existing pharmaceutical manufacturers, qualified specialists, and opportunities to use local production facilities to access neighboring markets. By meeting international quality standards, local manufacturing sites could also attract foreign partners seeking a production base in the region.

Bayan Group: Developing the Contract Manufacturing Model

One example of the development of contract manufacturing in Uzbekistan is Bayan Group, founded by Ulugbek Bayonovich Mamatkulov. The company considers this area one of the strategic pillars of its business.

The group operates two manufacturing facilities and specializes in sterile liquid dosage forms, including ampoules and infusion solutions. It has established a dedicated team to work with contract manufacturing clients. Each year, the company obtains more than ten new marketing authorizations for medicines.

Future plans include expanding production capabilities with the support of the European Bank for Reconstruction and Development. The company is considering investments in prefilled syringe (PFS) and vial production lines, as well as expanding cooperation with partners in neighboring countries. These developments would enable it to broaden its service portfolio and work with a wider range of clients.

Manufacturing as Part of a Competitive Strategy

For pharmaceutical businesses, contract manufacturing is a tool for managing investment, time to market, and commercial risks. A company can focus on developing its product portfolio, registration, marketing, and sales while entrusting manufacturing to a specialized partner.

For Uzbekistan, the development of the CDMO sector means more efficient use of industrial infrastructure, stronger professional expertise, new partnerships, and additional export opportunities. For patients, it could lead to a wider choice of medicines and more reliable supplies.

Manufacturing is therefore becoming more than an intermediate stage between drug development and market launch. It is an independent component of competitive strategy. Producing medicines with consistent quality, on time, and at an economically viable cost is becoming just as important as their development and promotion. This is where one of the key opportunities for pharmaceutical business growth and industry development in Uzbekistan is taking shape.

Powered by Froala Editor

Share with friends